I notice the filing content appears to be cut off mid-sentence, but there is sufficient substantive content to proceed with the article based on what is available.

Beam Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, disclosing condensed consolidated financial statements and pipeline updates.

Key Highlights

  • Cash and cash equivalents stood at $213,267 thousand as of September 30, 2026, down from $294,944 thousand at December 31, 2025, according to the filing.
  • Marketable securities totaled $830,606 thousand at September 30, 2026, compared with $950,266 thousand at December 31, 2025.
  • Total assets were reported at $1,269,072 thousand as of September 30, 2026, versus $1,481,177 thousand at year-end 2025.
  • Shares outstanding as of October 27, 2026 were 103,495,644, per the filing's cover page.
  • Active clinical programs include Phase 1/2 trials for risto-cel (sickle cell disease), BEAM-302 (alpha-1 antitrypsin deficiency), BEAM-301 (glycogen storage disease type 1a), and a Phase 1 healthy volunteer trial of BEAM-103, as described in the filing.
  • Accounts payable rose to $20,145 thousand at September 30, 2026 from $10,231 thousand at December 31, 2025, according to the balance sheet.

Beam Therapeutics Reports Q3 2026 Financials and Pipeline Progress

Beam Therapeutics Inc. (NASDAQ:BEAM), a Cambridge, Massachusetts-based genetic medicines company, submitted its quarterly report covering the period ended September 30, 2026. The filing reports that total current assets declined to $1,067,377 thousand from $1,268,688 thousand at December 31, 2025, driven primarily by reductions in both cash and cash equivalents and marketable securities. Total assets similarly decreased from $1,481,177 thousand to $1,269,072 thousand over the same period.

On the liabilities side, the filing shows accounts payable increased to $20,145 thousand from $10,231 thousand at year-end 2025, while accrued expenses and other current liabilities decreased to $40,100 thousand from $55,267 thousand. Property and equipment, net, was reported at $94,040 thousand, down from $104,500 thousand at December 31, 2025. Operating lease right-of-use assets were $92,994 thousand compared with $100,679 thousand at the prior year-end.

The filing describes several active clinical development programs. According to the company's disclosure, these include a Phase 1/2 trial of ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) for sickle cell disease, Phase 1/2 trials of BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type 1a, a Phase 1 healthy volunteer trial of BEAM-103, and an anticipated Phase 1/2 trial of BEAM-304 for phenylketonuria. The filing also references the potential for an accelerated approval path for BEAM-302 and the anticipated launch of risto-cel, characterizing these as forward-looking statements subject to the company's cautionary language and the risks described in its Risk Factors sections.

What Was Disclosed

Beam Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting a decrease in total assets to approximately $1.27 billion, a cash and marketable securities position of approximately $1.04 billion combined, and 103,495,644 shares outstanding as of October 27, 2026.